<DOC>
	<DOCNO>NCT01491217</DOCNO>
	<brief_summary>The main objective study determine maximum tolerate dose ( MTD ) recommend dose ( RD ) Oraxol® Phase I determine objective response rate Oraxol® Phase II .</brief_summary>
	<brief_title>A Study Oraxol® Gastric Cancer Patients</brief_title>
	<detailed_description>Administration Schedule : 1 cycle Oraxol® 28 day Oraxol® administrate twice week , total 6 time per cycle ( day 1,2,8,9,15 16 ) .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>1 . Patients must histologically cytologically diagnose advanced solid cancer . ( phaseI ) 2 . Advanced/metastatic/recurred gastric cancer ( PhaseII ) 3 . ECOG performance status ≤ 2 4 . Patients proper bone marrow , kidney , liver function patient remarkable dysfunction heart lung : WBC≥4000/mm3 ; Platelet ≥100,000/mm3 ; Hemoglobin≥9.0g/dL ; ANC≥ 1,500 /mm3 ; Creatinine ≤ 1.5mg/dL ; AST/ALT/ALP ≤ 3 X upper limit normal ; Total bilirubin ≤2.0mg/dL *AST/ALT/ALP ≤ 3 X upper limit normal &lt; 5 liver bone metastasis present 1 . Patients blood tumor ( ex , leukemia ) , uncontrolled infectious disease , neurologic disorder , metastasis CNS ileus ( patient require nonoral administration antibiotic treat active bacterial infection eligible , patient participate trial complete eradication control infection ) 2 . Patients receive bone marrow transplant receive bone marrow transplant . 3 . Patients medical history atrial ventricular arrhythmia congestive heart failure receive medical treatment myocardial infarction within 6 month .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Oraxol®</keyword>
	<keyword>oral paclitaxel</keyword>
	<keyword>paclitaxel</keyword>
	<keyword>HM30181A</keyword>
	<keyword>MTD</keyword>
	<keyword>DLT</keyword>
	<keyword>RD</keyword>
</DOC>